Literature DB >> 3772372

alpha-Bungarotoxin binds to low-affinity nicotine binding sites in rat brain.

S Wonnacott.   

Abstract

Reported differences in the pharmacology and distribution of [3H]nicotine and [125I]alpha-bungarotoxin binding sites in mammalian brain suggest that these ligands label separate receptor sites. Affinity purification of an alpha-bungarotoxin binding protein from rat brain failed to copurify the high-affinity nicotine binding site, which remained in the nonbound soluble fraction after the affinity chromatography step. This confirms the independence of these putative receptor sites. Nevertheless, the binding of [125I]alpha-bungarotoxin to P2 membranes was inhibited by (-)-nicotine (Ki = 9 X 10(-6) M), and this sensitivity was preserved after affinity purification. It is proposed that alpha-bungarotoxin binds to a population of low-affinity nicotine binding sites. Comparison of the enantiomers of nicotine in competition studies at both radioligand binding sites revealed an 80-fold preference for the (-) form at the high-affinity [3H]nicotine binding site, whereas the site labelled by [125I]alpha-bungarotoxin displayed little stereoselectivity. In this respect, the brain alpha-bungarotoxin binding site resembles the nicotinic acetylcholine receptor from Torpedo electric organ.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3772372     DOI: 10.1111/j.1471-4159.1986.tb13078.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  14 in total

1.  Nicotine receptor mapping.

Authors:  F Grünwald; H J Biersack; W Kuschinsky
Journal:  Eur J Nucl Med       Date:  1996-08

Review 2.  Regulation of nicotinic acetylcholine receptors by protein phosphorylation.

Authors:  K Miles; R L Huganir
Journal:  Mol Neurobiol       Date:  1988       Impact factor: 5.590

Review 3.  Molecular studies of the neuronal nicotinic acetylcholine receptor family.

Authors:  J Lindstrom; R Schoepfer; P Whiting
Journal:  Mol Neurobiol       Date:  1987       Impact factor: 5.590

4.  Acute nicotine-induced tachyphylaxis is differentially manifest in the limbic system.

Authors:  Yantao Zuo; Hanbing Lu; D Bruce Vaupel; Yi Zhang; Svetlana I Chefer; William R Rea; Anna V Moore; Yihong Yang; Elliot A Stein
Journal:  Neuropsychopharmacology       Date:  2011-07-27       Impact factor: 7.853

5.  Chronic nicotine treatment changes differentially the effects of acute nicotine on the three main dopamine metabolites in mouse striatum.

Authors:  T Leikola-Pelho; J Heinämäki; I Laakso; L Ahtee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-10       Impact factor: 3.000

6.  Relations between structure and nicotine-like activity: X-ray crystal structure analysis of (-)-cytisine and (-)-lobeline hydrochloride and a comparison with (-)-nicotine and other nicotine-like compounds.

Authors:  R B Barlow; O Johnson
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

7.  The developing cholinergic system as target for environmental toxicants, nicotine and polychlorinated biphenyls (PCBs): implications for neurotoxicological processes in mice.

Authors:  P Eriksson; E Ankarberg; H Viberg; A Fredriksson
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

8.  Mice deficient in the alpha7 neuronal nicotinic acetylcholine receptor lack alpha-bungarotoxin binding sites and hippocampal fast nicotinic currents.

Authors:  A Orr-Urtreger; F M Göldner; M Saeki; I Lorenzo; L Goldberg; M De Biasi; J A Dani; J W Patrick; A L Beaudet
Journal:  J Neurosci       Date:  1997-12-01       Impact factor: 6.167

Review 9.  Nicotine modulation of fear memories and anxiety: Implications for learning and anxiety disorders.

Authors:  Munir Gunes Kutlu; Thomas J Gould
Journal:  Biochem Pharmacol       Date:  2015-07-29       Impact factor: 5.858

10.  Differential regulation of alpha7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers.

Authors:  Sharon Mexal; Ralph Berger; Judy Logel; Randal G Ross; Robert Freedman; Sherry Leonard
Journal:  J Mol Neurosci       Date:  2009-08-13       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.